Gefitinib
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00317 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 29 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | fibromatosis, gingival | KG + DL |
| 2 | fibroma of lung | KG + DL |
| 3 | inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia | KG + DL |
| 4 | hamartoma of lung | KG + DL |
| 5 | lung hilum carcinoma | KG + DL |
| 6 | lung benign neoplasm | KG + DL |
| 7 | Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndrome | KG + DL |
| 8 | pulmonary sulcus neoplasm | KG + DL |
| 9 | lung germ cell tumor | KG + DL |
| 10 | junctional epidermolysis bullosa | KG + DL |
| 11 | ovarioleukodystrophy | KG + DL |
| 12 | junctional epidermolysis bullosa, non-Herlitz type | KG + DL |
| 13 | dehydratase deficiency | KG + DL |
| 14 | Ewing sarcoma | KG + DL |
| 15 | uterine corpus sarcoma | KG + DL |
| 16 | giant cell tumor of soft tissue | KG + DL |
| 17 | synovial chondromatosis | KG + DL |
| 18 | orbit sarcoma | KG + DL |
| 19 | sarcoma, avian | KG + DL |
| 20 | bone sarcoma | KG + DL |
| 21 | ovarian myxoid liposarcoma | KG + DL |
| 22 | liposarcoma | KG + DL |
| 23 | ganglioneuroblastoma (disease) | KG + DL |
| 24 | vertebral anomalies and variable endocrine and T-cell dysfunction | KG + DL |
| 25 | lung adenocarcinoma | KG + DL |
| 26 | dermatofibrosarcoma protuberans | KG + DL |
| 27 | retroperitoneal neoplasm | KG + DL |
| 28 | sarcoma of cervix uteri | KG + DL |
| 29 | neuroblastoma | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.